Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Thiogenesis Therapeutics Corp (TTI.VN)

Thiogenesis Therapeutics Corp (TTI.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 26,436
  • Shares Outstanding, K 51,836
  • Annual Sales, $ 0 K
  • Annual Income, $ -3,146 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta -0.11
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 12.28
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.15
  • Most Recent Earnings $-0.05 on 11/26/25
  • Next Earnings Date N/A
  • Annual Dividend & Yield (Fwd) N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING:

    TSX Biotechnology

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.500 unch
on 03/04/26
0.640 -21.87%
on 02/06/26
-0.090 (-15.25%)
since 02/04/26
3-Month
0.500 unch
on 03/04/26
0.660 -24.24%
on 01/06/26
-0.130 (-20.63%)
since 12/04/25
52-Week
0.500 unch
on 03/04/26
0.880 -43.18%
on 07/07/25
-0.150 (-23.08%)
since 03/03/25

Most Recent Stories

More News
Thiogenesis Therapeutics Announces Investigator-Initiated Study in Nephropathic Cystinosis and Provides Program Update

San Diego, California--(Newsfile Corp. - February 2, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing...

TTI.VN : 0.500 (-1.96%)
TTIPF : 0.4000 (unch)
Thiogenesis Presents Phase 2 (EU) MELAS Data at Mitocon 2026

Highlighting Optimized Once-Daily Weight-Based Dosing and Clinically Meaningful Fatigue ImprovementSan Diego, California--(Newsfile Corp. - January 23, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI)...

TTI.VN : 0.500 (-1.96%)
TTIPF : 0.4000 (unch)
Thiogenesis Therapeutics' MELAS Abstract Accepted for Late-Breaking News Presentation at Mitocon 2026

San Diego, California--(Newsfile Corp. - January 13, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing...

TTI.VN : 0.500 (-1.96%)
TTIPF : 0.4000 (unch)
Thiogenesis to Present Clinical Updates in MELAS and Leigh Syndrome Spectrum at UMDF Bench-to-Bedside Webinar

Dr. Rioux Will Present on Phase 2 MELAS Program & Upcoming Phase 2a Leigh Syndrome TrialSan Diego, California--(Newsfile Corp. - January 5, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF)...

TTI.VN : 0.500 (-1.96%)
TTIPF : 0.4000 (unch)
Thiogenesis Therapeutics Expands on Plans for Phase 3 Pivotal Trial of TTI-0102 in Nephropathic Cystinosis

IND expected in early 2026; TTI-0102 designed to improve tolerability & simplify dosingSan Diego, California--(Newsfile Corp. - November 24, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX:...

TTI.VN : 0.500 (-1.96%)
TTIPF : 0.4000 (unch)
Thiogenesis Reports Positive Interim Phase 2 Trial Results for MELAS and Announces Pipeline Advancements in Leigh Syndrome and Cystinosis

Trial achieved biological proof-of-concept, dose discovery and biomarker improvementSan Diego, California--(Newsfile Corp. - November 4, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF)...

TTI.VN : 0.500 (-1.96%)
TTIPF : 0.4000 (unch)
Thiogenesis Announces Extension to Investor Relations Agreement

San Diego, California--(Newsfile Corp. - October 3, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (Thiogenesis or the Company) a clinical-stage biotechnology company developing disulfides that drive...

TTI.VN : 0.500 (-1.96%)
TTIPF : 0.4000 (unch)
Thiogenesis Reports on 2025 Annual General Meeting of Shareholders and Provides Corporate Update

San Diego, California--(Newsfile Corp. - September 11, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biopharmaceutical company developing...

TTI.VN : 0.500 (-1.96%)
TTIPF : 0.4000 (unch)
Thiogenesis Receives Final Acceptance from TSXV for Its Over-Subscribed Non-Brokered Private Placement of Common Shares

San Diego, California--(Newsfile Corp. - August 14, 2025) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") is pleased to announce that, further to its news release of August...

TTI.VN : 0.500 (-1.96%)
Thiogenesis Raises over C$4.14 Million in Non-Brokered Private Placement of Common Shares

San Diego, California--(Newsfile Corp. - August 1, 2025) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") is pleased to announce that, further to its news releases of July...

TTI.VN : 0.500 (-1.96%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 30%. The market has entered oversold territory.

See More Share

Business Summary

Thiogenesis Therapeutics Corp is a clinical-stage biotech company. The Company is developing thiol-active therapeutic compounds, that are prodrugs, used to treat unmet pediatric medical needs. TTI-0102, the Company's compound, was developed to address the obstacles facing previous thiol-based drugs,...

See More

Key Turning Points

3rd Resistance Point 0.527
2nd Resistance Point 0.523
1st Resistance Point 0.517
Last Price 0.500
1st Support Level 0.507
2nd Support Level 0.503
3rd Support Level 0.497

See More

52-Week High 0.880
Fibonacci 61.8% 0.735
Fibonacci 50% 0.690
Fibonacci 38.2% 0.645
Last Price 0.500
52-Week Low 0.500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar